Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy.

Abstract

Androgen deprivation therapy (ADT) and bone metastases are the most important risk factors for developing skeletal complications (eg, bone loss, pathologic fractures) in prostate cancer (PC) patients with locally advanced and metastatic disease. Bisphosphonates, which inhibit excessive osteoclast activity caused by ADT and bone metastases, have proven to be safe and effective in preventing skeletal complications and presently are the standard of care in patients with metastatic disease. Bisphosphonates should be considered for use in all PC patients with locally advanced disease initiating ADT for an intended duration of at least 1 year, especially those with a low baseline bone mineral density.

• Authors: Ron S Israeli
• Journal: Reviews in urology (Rev Urol) Vol. 10 Issue 2 Pg. 99-110 ( 2008) ISSN: 1523-6161 [Print] United States
• PMID: 18660863 (Publication Type: Journal Article)